Skip to content

Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments

Assessment of Physician Consideration of Electronic Patient Reported Outcomes, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus Erythematosus, on the Frequency of Therapeutic Adjustments

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05927688
Acronym
CAPTAIN
Enrollment
352
Registered
2023-07-03
Start date
2023-07-18
Completion date
2027-07-31
Last updated
2025-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus

Brief summary

Inflammatory rheumatic diseases affect 1% of the population. Treatment of such diseases should be based on disease activity, safety issues and other patient characteristics such as comorbidities (EULAR, 2022), leading to a higher risk of cardiovascular diseases. To this end, the general treat-to-target approach, as recommended in the EULAR guidance, may require several successive treatment lines based on updates to the patients' profile and close monitoring as the keystone of its implementation. Regular feedback from patients could be used to fuel such strategies. This feedback can be collected using an ePRO (electronic Patient Reported Outcome). The purpose of this study is therefore to assess patient management using the information provided by patients through e-PROs, which will transfer the data provided by the patient to the physician and will notify the investigators via email when a patient has completed a form (no data interpretation or alerts). The hypothesis is that the more physicians are provided with insights into their patients' health, the more they will function in a treat-to-target approach and the more often they will tend to adjust their patients' treatments.

Interventions

BEHAVIORALTherapeutic management following access by the physician to his patient's ePROs

Therapeutic management following access by the physician to his patient's ePROs

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men or women of at least 18 years of age * Diagnosed with (at least) one of the following autoimmune diseases: * Rheumatoid arthritis (RA) according to the 2010 EULAR/ACR classification criteria, * Gout according to the 2015 EULAR/ACR classification criteria, * Systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria * Sjogren's Syndrome according to the 2016 EULAR/ACR classification criteria * According to local regulations, patient has expressed his/her non-opposition (for France) or has provided written informed consent (for Switzerland and Germany) to participate in the study * Patient has access to the internet, a functioning email address and a mobile phone number * Patient physically and mentally able to use a computer tool connected to the Internet * Only in Switzerland & Germany : patient is covered by a health insurance plan

Exclusion criteria

* Any neurodegenerative disease that alters cognitive faculties * Refractory cancer * Patients who do not have access to the Internet and/or do not master its use in the context of this protocol * Unwillingness or inability to adhere to study protocol (language barriers, cognitive disorders…) Subject who is compulsorily detained for psychiatric treatment * Patient who cannot be followed for 2 years by the investigating physician * Patient over the age of legal majority who is protected, or deprived of liberty by judicial or administrative decision (vulnerable subject) * Patient with an estimated life expectancy shorter than 1 year

Design outcomes

Primary

MeasureTime frameDescription
Frequency of therapeutic adjustments12 monthsTo assess the relationship between the frequency of therapeutic adjustments over a 12-month period made by rheumatologists who were provided regular patient reported outcomes (PROs) and their use of an electronic platform providing them with these data.

Secondary

MeasureTime frameDescription
Frequency of flares and exacerbationDay 1To assess the fluctuation of disease activity and flares - as perceived by the patient
RAPID 3 (Routine Assessment of Patient Index Data 3) questionnaire to measure the disease scoreDay 1To assess the overall health of patients
HAQ score (Health Assessment Questionnaire) for health assessmentDay 1To assess the overall health of patients
Frequency of therapeutic adjustments6 monthsTo assess the relationship between the frequency of therapeutic adjustments over a 6-month period made by rheumatologists who were provided regular patient reported outcomes (PROs) and their use of an electronic platform providing them with these data.
PEPPI score (Perceived efficacy in patient-physician interactions)6 monthsTo assess the patient-physician relationship
Number of times patients logged in to the platform6 monthsTo assess the use of the patient portal by patients and associated satisfaction
Number of times physicians logged in to the platform6 monthsTo assess the viewing of patient-reported data by physicians
IPAQ score (International Physical Activity Questionnaire) to measure physical activityDay 1To assess patient's physical activity over time

Countries

France

Contacts

Primary ContactJacques-Eric GOTTENBERG, Professor
jacques-eric.gottenberg@chru-strasbourg.fr3 88 12 79 53
Backup ContactJacques-Eric GOTTENBERG, MD, PhD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026